MX2022015044A - Formulaciones y metodos para tratar el sindrome de dificultad respiratoria aguda, asma o rinitis alergica. - Google Patents
Formulaciones y metodos para tratar el sindrome de dificultad respiratoria aguda, asma o rinitis alergica.Info
- Publication number
- MX2022015044A MX2022015044A MX2022015044A MX2022015044A MX2022015044A MX 2022015044 A MX2022015044 A MX 2022015044A MX 2022015044 A MX2022015044 A MX 2022015044A MX 2022015044 A MX2022015044 A MX 2022015044A MX 2022015044 A MX2022015044 A MX 2022015044A
- Authority
- MX
- Mexico
- Prior art keywords
- asthma
- allergic rhinitis
- formulations
- methods
- respiratory distress
- Prior art date
Links
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title abstract 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 title abstract 5
- 206010039085 Rhinitis allergic Diseases 0.000 title abstract 4
- 201000010105 allergic rhinitis Diseases 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 title 1
- 208000024716 acute asthma Diseases 0.000 title 1
- 208000006673 asthma Diseases 0.000 abstract 4
- 239000004469 amino acid formulation Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032185P | 2020-05-29 | 2020-05-29 | |
| US202063080470P | 2020-09-18 | 2020-09-18 | |
| US202063088813P | 2020-10-07 | 2020-10-07 | |
| US202163136404P | 2021-01-12 | 2021-01-12 | |
| PCT/US2021/034807 WO2021243183A1 (en) | 2020-05-29 | 2021-05-28 | Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015044A true MX2022015044A (es) | 2023-01-04 |
Family
ID=78722883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015044A MX2022015044A (es) | 2020-05-29 | 2021-05-28 | Formulaciones y metodos para tratar el sindrome de dificultad respiratoria aguda, asma o rinitis alergica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230201151A1 (enExample) |
| EP (1) | EP4157218A4 (enExample) |
| JP (1) | JP2023531872A (enExample) |
| KR (1) | KR20230018474A (enExample) |
| CN (1) | CN115697301A (enExample) |
| AU (1) | AU2021280328A1 (enExample) |
| BR (1) | BR112022024033A2 (enExample) |
| CA (1) | CA3177780A1 (enExample) |
| MX (1) | MX2022015044A (enExample) |
| WO (1) | WO2021243183A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116036277B (zh) * | 2022-07-19 | 2023-10-31 | 广州国家实验室 | 氯离子在预防、治疗冠状病毒所致疾病中的应用 |
| US11878073B1 (en) | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686340B2 (en) * | 2001-06-19 | 2004-02-03 | Matthias Rath | Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells |
| CN104207146A (zh) * | 2014-07-26 | 2014-12-17 | 胡安然 | 呼吸系统疾病全营养配方食品 |
| WO2019070759A1 (en) * | 2017-10-02 | 2019-04-11 | University Of Florida Research Foundation Incorporated | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS |
| US12109191B2 (en) * | 2017-10-02 | 2024-10-08 | Amilyfe, Llc | Materials and methods for inhibiting tumor growth |
| EP3873453A4 (en) * | 2018-10-30 | 2022-08-03 | University of Florida Research Foundation, Incorporated | AMINO ACID COMPOSITIONS AND METHODS OF TREATMENT OF CF |
-
2021
- 2021-05-28 CA CA3177780A patent/CA3177780A1/en active Pending
- 2021-05-28 AU AU2021280328A patent/AU2021280328A1/en active Pending
- 2021-05-28 EP EP21812111.9A patent/EP4157218A4/en active Pending
- 2021-05-28 JP JP2022573664A patent/JP2023531872A/ja active Pending
- 2021-05-28 WO PCT/US2021/034807 patent/WO2021243183A1/en not_active Ceased
- 2021-05-28 MX MX2022015044A patent/MX2022015044A/es unknown
- 2021-05-28 US US18/000,177 patent/US20230201151A1/en active Pending
- 2021-05-28 KR KR1020227046211A patent/KR20230018474A/ko active Pending
- 2021-05-28 BR BR112022024033A patent/BR112022024033A2/pt not_active Application Discontinuation
- 2021-05-28 CN CN202180038692.7A patent/CN115697301A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4157218A4 (en) | 2024-06-26 |
| WO2021243183A1 (en) | 2021-12-02 |
| WO2021243183A8 (en) | 2022-01-13 |
| EP4157218A1 (en) | 2023-04-05 |
| AU2021280328A1 (en) | 2022-11-17 |
| JP2023531872A (ja) | 2023-07-26 |
| US20230201151A1 (en) | 2023-06-29 |
| CA3177780A1 (en) | 2021-12-02 |
| KR20230018474A (ko) | 2023-02-07 |
| CN115697301A (zh) | 2023-02-03 |
| BR112022024033A2 (pt) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021191630A8 (en) | Coronavirus vaccine | |
| CA2474479A1 (en) | Composition for inhalation | |
| MX2025004666A (es) | Uso de oxido nitrico inhalado para el tratamiento de la hipertension pulmonar asociada con enfermedades pulmonares | |
| MY208001A (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| MY200975A (en) | "Compositions Comprising Amino acids for use in the Treatment of Mitochondrial Dysfunction-Related Diseases" | |
| PH12019501469A1 (en) | Compositions and methods for treating biofilms | |
| JP2017532343A5 (enExample) | ||
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2011010781A (es) | Una crema medicinal hecha con sulfadiazina de plata y quitosano y un proceso para hacerla. | |
| PH12021551268A1 (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| NO20063047L (no) | Vandige ciclesonidsuspensjoner for forstoving | |
| WO2018094023A3 (en) | Cyclic dipeptides and wound healing | |
| WO2021243183A8 (en) | Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis | |
| MX2023006611A (es) | Acido hidroxiestearico para inducir la generacion de peptidos antimicrobianos. | |
| WO2022197720A3 (en) | Compositions and methods for treating coronavirus infection | |
| ZA202402553B (en) | Substituted s-alaninate derivatives | |
| MX2017016227A (es) | Peptidos anti-infecciosos de amplio espectro. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| WO2019099860A3 (en) | Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing | |
| EP3295932A3 (en) | Stable odf composition containing hardly soluble therapeutic agent | |
| WO2022043273A3 (en) | Oral care composition comprising a fructanase | |
| PT4199922T (pt) | Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2- il)carbamoil)ciclopentano-1-carboxílico para uso no tratamento de doenças das vias respiratórias | |
| EP4534146A3 (en) | Dimenhydrinate and calcium pantothenate for preventing and treating muscular disease | |
| WO2023240193A3 (en) | Fitusiran for the treatment of hemophilia a and b in pediatric patients | |
| JOP20210315B1 (ar) | إستر لـ -حمض أسيتيك أيزو بروبيل لعلاج السعال المزمن |